Literature DB >> 11046041

CD30 signals integrate expression of cytotoxic effector molecules, lymphocyte trafficking signals, and signals for proliferation and apoptosis.

H Muta1, L H Boise, L Fang, E R Podack.   

Abstract

Although CD30 has long been recognized as an important marker on many lymphomas of diverse origin and as activation molecule on B cells and T cells, its primary function has remained obscure. We now report that CD30 signals may serve to inhibit effector cell activity by integrating gene expression changes of several pathways important for cytotoxic NK and T cell effector function. In the large granular lymphoma line YT, CD30 signals down-regulate the expression of cytotoxic effector molecules, Fas ligand, perforin, granzyme B, and abrogate cytotoxicity. c-myc, a regulator of proliferation and an upstream regulator of Fas ligand expression, is completely suppressed by CD30. Furthermore, CD30 signals strongly induce CCR7, suggesting a role for CD30 signals in the homing of lymphocytes to lymph nodes. The up-regulation of Fas, death receptor 3, and TNF-related apoptosis-inducing ligand by CD30 indicates an increase in susceptibility to apoptotic signals whereas up-regulation of TNFR-associated factor 1 and cellular inhibitor of apoptosis 2 protect cells from certain types of apoptosis. Using gene microarrays, 750 gene products were induced and 90 gene products were suppressed >2-fold by CD30 signals. Signals emanating from CD30 use both TNFR-associated factor 2-dependent and -independent pathways. The integration of CD30 signals in a lymphoma line suggests that CD30 can down-modulate lymphocyte effector function and proliferation while directing the cells to lymph nodes and increasing their susceptibility to certain apoptotic signals. These studies may provide a molecular mechanism for the recently observed CD30-mediated suppression of CTL activity in vivo in a diabetes model.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11046041     DOI: 10.4049/jimmunol.165.9.5105

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  18 in total

1.  cIAP2 is highly expressed in Hodgkin-Reed-Sternberg cells and inhibits apoptosis by interfering with constitutively active caspase-3.

Authors:  Horst Dürkop; Burkhard Hirsch; Corinna Hahn; Harald Stein
Journal:  J Mol Med (Berl)       Date:  2005-11-25       Impact factor: 4.599

2.  Early CD30 signaling is critical for adoptively transferred CD4+CD25+ regulatory T cells in prevention of acute graft-versus-host disease.

Authors:  Robert Zeiser; Vu H Nguyen; Jing-Zhou Hou; Andreas Beilhack; Elizabeth Zambricki; Martin Buess; Christopher H Contag; Robert S Negrin
Journal:  Blood       Date:  2006-10-26       Impact factor: 22.113

Review 3.  CD30+ Lymphoproliferative Disorders of the Skin.

Authors:  Maxwell B Sauder; John T O'Malley; Nicole R LeBoeuf
Journal:  Hematol Oncol Clin North Am       Date:  2017-04       Impact factor: 3.722

Review 4.  CD30+ neoplasms of the skin.

Authors:  Madeleine Duvic
Journal:  Curr Hematol Malig Rep       Date:  2011-12       Impact factor: 3.952

5.  CD30 ligand/CD30 interaction is involved in pathogenesis of inflammatory bowel disease.

Authors:  Shinichi Somada; Hiromi Muta; Kazuhiko Nakamura; Xun Sun; Kuniomi Honda; Eikichi Ihara; Hirotada Akiho; Ryoichi Takayanagi; Yasunobu Yoshikai; Eckhard R Podack; Kenzaburo Tani
Journal:  Dig Dis Sci       Date:  2012-03-27       Impact factor: 3.199

Review 6.  A comprehensive review on the role of co-signaling receptors and Treg homeostasis in autoimmunity and tumor immunity.

Authors:  Prabhakaran Kumar; Palash Bhattacharya; Bellur S Prabhakar
Journal:  J Autoimmun       Date:  2018-08-31       Impact factor: 7.094

Review 7.  Tumor necrosis factor/tumor necrosis factor receptor family members that positively regulate immunity.

Authors:  Takanori So; Seung-Woo Lee; Michael Croft
Journal:  Int J Hematol       Date:  2006-01       Impact factor: 2.490

8.  Quantitative analysis of human immunodeficiency virus type 1-infected CD4+ cell proteome: dysregulated cell cycle progression and nuclear transport coincide with robust virus production.

Authors:  Eric Y Chan; Wei-Jun Qian; Deborah L Diamond; Tao Liu; Marina A Gritsenko; Matthew E Monroe; David G Camp; Richard D Smith; Michael G Katze
Journal:  J Virol       Date:  2007-05-09       Impact factor: 5.103

Review 9.  CD30: from basic research to cancer therapy.

Authors:  Hiromi Muta; Eckhard R Podack
Journal:  Immunol Res       Date:  2013-12       Impact factor: 2.829

Review 10.  Antibody Drug Conjugates (ADCs): Changing the Treatment Landscape of Lymphoma.

Authors:  Deepa Jagadeesh; Mitchell R Smith
Journal:  Curr Treat Options Oncol       Date:  2016-10
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.